Sanofi (SNY)
44.24
-0.09 (0.20%)
Upcoming Events
Latest Headlines
BofA Securities Reiterates Neutral Rating on Sanofi (SAN:FP) (SNY)
September 4, 2026 6:07 AM - StreetInsider
Form N-PX Sanofi For: Jun 30
August 25, 2026 6:06 AM - SEC Filing
Sanofi (SAN:FP) (SNY) PT Lowered to EUR82 at Morgan Stanley
August 11, 2026 4:37 AM - StreetInsider
Form 6-K Sanofi For: Aug 06
August 6, 2026 6:08 AM - SEC Filing
Sanofi (SAN:FP) (SNY) PT Lowered to EUR78 at UBS
July 31, 2026 5:18 AM - StreetInsider
Sanofi (SAN:FP) (SNY) PT Lowered to EUR78 at Citi
July 31, 2026 5:04 AM - StreetInsider
Press Release: Sanofi’s half-year financial report for 2026
July 30, 2026 9:38 AM - Globe NewsWire
Form 6-K Sanofi For: Jun 30
July 30, 2026 7:34 AM - SEC Filing
Form 6-K Sanofi For: Jun 30
July 30, 2026 6:29 AM - SEC Filing
Sanofi (SNY) Tops Q2 EPS by 100c
July 30, 2026 2:13 AM - StreetInsider
Form 13F-HR Sanofi For: Jun 30
July 28, 2026 6:15 AM - SEC Filing
Form 6-K Sanofi For: Jul 27
July 27, 2026 6:10 AM - SEC Filing
Form SCHEDULE 13G/A Sanofi Filed by: Amundi
July 22, 2026 9:50 AM - SEC Filing
Sanofi reshapes executive committee effective September 2026
July 21, 2026 12:05 PM - StreetInsider
Press Release: Sanofi evolves its Executive Committee to support its next strategic chapter
July 21, 2026 12:00 PM - Globe NewsWire
Form 6-K Sanofi For: Jul 17
July 17, 2026 6:04 AM - SEC Filing
US FDA approves Sanofi's wearable injector form of blood cancer drug
July 10, 2026 8:56 AM - StreetInsider
FDA clears Sanofi's Sarclisa Escena via on-body injector for myeloma
July 10, 2026 8:36 AM - StreetInsider
Press Release: Sanofi’s subcutaneous Sarclisa Escena approved in the US as first anticancer treatment administered via on-body injector
July 10, 2026 8:35 AM - Globe NewsWire
EU seeks feedback on Sanofi commitments over flu vaccine probe
July 8, 2026 6:02 AM - StreetInsider
Sanofi (SAN:FP) (SNY) PT Lowered to EUR86 at Morgan Stanley
July 8, 2026 4:49 AM - StreetInsider
Form 6-K Sanofi For: Jul 07
July 7, 2026 9:02 AM - SEC Filing
Form 11-K Sanofi For: Dec 31
June 30, 2026 1:28 PM - SEC Filing
Form 11-K Sanofi For: Dec 31
June 30, 2026 12:54 PM - SEC Filing
Form NT 11-K Sanofi For: Dec 31
June 30, 2026 11:49 AM - SEC Filing
Form NT 11-K Sanofi For: Dec 31
June 30, 2026 11:45 AM - SEC Filing
Form 6-K Sanofi For: Jun 24
June 24, 2026 8:44 AM - SEC Filing
Form 6-K Sanofi For: Jun 22
June 22, 2026 8:43 AM - SEC Filing
Novel Patented Myelin Drug-Discovery Strategy Targets Massive Unmet Need in Multiple Sclerosis
June 22, 2026 8:30 AM - StreetInsider
Sanofi (SNY) call put ratio 8.4 calls to 1 put with a focus on July 45 calls
June 22, 2026 6:04 AM - StreetInsider
Press Release: Sanofi appoints Paulo Fontoura as Global Head of R&D
June 22, 2026 2:00 AM - Globe NewsWire
Sanofi wins Japan approval for Sarclisa SC in multiple myeloma
June 19, 2026 6:31 AM - StreetInsider
Press Release: Sanofi’s Sarclisa subcutaneous formulation approved in Japan for patients with multiple myeloma
June 19, 2026 6:31 AM - Globe NewsWire
Sanofi (SAN:FP) (SNY) PT Lowered to EUR95 at Deutsche Bank
June 15, 2026 5:12 AM - StreetInsider
Press Release: Sanofi’s Tzield approved in the US as the first disease-modifying therapy for patients recently diagnosed with stage 3 type 1 diabetes
June 12, 2026 6:10 PM - Globe NewsWire
Form 6-K Sanofi For: Jun 12
June 12, 2026 11:42 AM - SEC Filing
Guggenheim Defending Dianthus Therapeutics (DNTH): 'We reiterate our positive view'
June 10, 2026 4:10 PM - StreetInsider
TD Cowen Defending Dianthus Therapeutics (DNTH): 'We see weakness as a buying opportunity'
June 10, 2026 1:37 PM - StreetInsider
Raymond James on Dianthus Therapeutics (DNTH) Amid 15% Down Day: 'We See Overall Positive Readthrough to Claseprubart'
June 10, 2026 1:01 PM - StreetInsider
Form 6-K Sanofi For: Jun 08
June 8, 2026 6:07 AM - SEC Filing
Full Article List
